Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.3K citations · Full text

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.5K citations

Hematological Malignancy, Cell Therapy, Immunotherapy +11

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 990 citations · Full text

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld, Hervé Avet‐Loiseau, Sagar Lonial et al. · Blood · 2016 · 907 citations · Full text

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Ichiro Hanamura, Peter Stewart, Yongsheng Huang et al. · Blood · 2006 · 476 citations · Full text